Cadonilimab Subgroup Analyses in COMPASSION-16

Key Takeaways

• Across the analyzed subgroups, progression-free survival consistently favored cadonilimab.
• Overall survival was also reported as prolonged with the addition of cadonilimab.
• The subgroup framework spanned prespecified clinical and biomarker strata within the study population.

The setting was first-line cadonilimab plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Investigators examined whether the benefit seen in the overall trial remained directionally similar across prespecified clinical and biomarker groups. Hazard ratios for progression-free survival favored cadonilimab in every subgroup included in the abstract. The subgroup results followed the overall efficacy pattern from the parent study across the examined strata.

The phase 3 COMPASSION-16 trial enrolled patients with persistent, recurrent, or metastatic cervical cancer, and this report focused on its subgroup analysis. The analysis examined efficacy outcomes within patient subsets and whether the main study signal was maintained across those predefined categories. The dual primary endpoints were progression-free survival, assessed by blinded independent central review according to RECIST 1.1, and overall survival. Objective response rate was the secondary endpoint identified in the abstract. The focus remained on consistency of the trial findings across baseline patient profiles rather than on any single stratum.

Prespecified subgroup categories were bevacizumab use, prior concurrent chemoradiotherapy, PD-L1 combined positive score, metastatic disease at baseline, platinum use, and age. These variables covered prior treatment exposure, biomarker expression, disease burden at baseline, treatment accompaniment, and age within the enrolled population. Within that framework, progression-free survival favored cadonilimab across each subgroup included in the analysis. Overall survival also moved in the same direction with the addition of cadonilimab across the examined strata. The subgroup analysis showed a directionally consistent pattern across the clinical and biomarker categories evaluated by investigators.

The investigators interpreted these findings as consistent with the primary COMPASSION-16 results across diverse patient profiles represented in the trial. Their interpretation emphasized concordance with the broader study results rather than an efficacy signal limited to one clinical subgroup. The abstract did not provide subgroup-specific numerical estimates or interaction statistics for the listed strata. The summary therefore remained at the level of direction and consistency rather than detailed stratum-by-stratum effect sizes. Even within that scope, the subgroup findings aligned with the main trial pattern across prespecified groups.